Janssen Research and Development, LLC: New Two-year Guselkumab Data Show Patients with Moderate to Severe ... - PR Newswire (press release)

Janssen Research and Development, LLC: New Two-year Guselkumab Data Show Patients with Moderate to Severe ...
PR Newswire (press release)
Janssen Research & Development, LLC (Janssen) presented today new longer-term data from the open-label extension of the VOYAGE 1 trial demonstrating consistent rates of skin clearance with guselkumab treatment through week 100 among patients with ...and more »